Anti-Rheumatic Drugs - Bangladesh

The revenue in the Anti-Rheumatic Drugs market in Bangladesh is estimated to reach US$18.58m by 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 2.34%, leading to a market volume of US$20.85m by 2029.
When compared globally, United States is projected to generate the highest revenue of US$34.70bn in 2024.
Bangladesh's pharmaceutical industry is witnessing a growing demand for affordable and accessible anti-rheumatic drugs to address the rising prevalence of rheumatic diseases in the country.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The Anti-Rheumatic Drugs market in Bangladesh has been steadily growing over the years due to various factors.

Customer preferences: Bangladesh has a high prevalence of rheumatoid arthritis, which has led to an increase in demand for Anti-Rheumatic Drugs. Patients are willing to spend on these medications as they provide relief from the pain and inflammation associated with the disease. Additionally, the availability of affordable generic versions of these drugs has made them accessible to a larger population.

Trends in the market: The Anti-Rheumatic Drugs market in Bangladesh has witnessed a shift towards biologics, which are more effective in treating rheumatoid arthritis. Patients are willing to pay a premium for these drugs as they provide better outcomes in terms of disease remission and improved quality of life. The market is also witnessing an increase in the number of combination therapies, which provide a more comprehensive approach to treating the disease.

Local special circumstances: Bangladesh has a large population, which has led to a rise in the number of rheumatoid arthritis cases. However, the country has a shortage of rheumatologists, which has led to a delay in diagnosis and treatment. This has resulted in a higher demand for Anti-Rheumatic Drugs as patients seek relief from the symptoms of the disease.

Underlying macroeconomic factors: The Anti-Rheumatic Drugs market in Bangladesh is driven by the country's economic growth and increasing healthcare spending. The government has initiated various programs to improve healthcare infrastructure and increase access to healthcare services, which has led to an increase in demand for Anti-Rheumatic Drugs. Additionally, the rise in disposable income has made these drugs more affordable for patients.In conclusion, the Anti-Rheumatic Drugs market in Bangladesh is growing due to the high prevalence of rheumatoid arthritis, the shift towards biologics, and the increase in healthcare spending. However, the shortage of rheumatologists remains a challenge for the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. The market has experienced significant growth during the past two decades, and pharma revenues worldwide totaled 1.48 trillion U.S. dollars in 2022.